Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11128099 | 0.76 | KMT2A (0.47) | SMN1; SMN2MEN1KMT2AATMLMNA | |
| SCHEMBL29396830 | 0.74 | ALDH1A1 (0.37) | SMN1; SMN2MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL787101 | 0.74 | ATM (0.58) | CTSKSMN1; SMN2ATMLMNAHPGD | |
| SCHEMBL445249 | 0.73 | RAB9A (0.49) | SMN1; SMN2MEN1KMT2AATMLMNA | |
| SCHEMBL3766250 | 0.73 | GAA (0.54) | SMN1; SMN2MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3197830 | 0.72 | EGFR (0.59) | SMN1; SMN2MEN1KMT2AATMLMNA | |
| SCHEMBL3272690 | 0.72 | FFAR2 (0.41) | MEN1KMT2A | |
| SCHEMBL3766245 | 0.72 | CHRNB2 (0.41) | POLB | |
| SCHEMBL22155015 | 0.72 | SMARCA2 (0.54) | SMN1; SMN2MEN1KMT2ALMNAHPGD | |
| SCHEMBL17443443 | 0.72 | ATM (0.46) | CTSKSMN1; SMN2MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| WO-2007088478-A1 | INDAZOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER PRODUCTS INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| WO-2005082897-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| US-6828317-B2 | Bactericides; gramnegative, grampositive bacteria | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | disclosed |
| EP-1472247-A1 | ANTIMICROBIAL THIADIAZINONE DERIVATIVES USEFUL IN TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | LABORATORIOS VITA, S.A. (ES) | 2004-07-29 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| EP-1401834-A1 | NEW DERIVATIVES OF OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | LABORATORIOS VITA, S.A. (ES) | 2004-03-31 | — | — | EP | disclosed |
| US-20040014746-A1 | Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections | LEUHR GARY W (US) | 2004-01-22 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| WO-2003066631-A1 | ANTIMICROBIAL THIADIAZINONE DERIVATIVES USEFUL IN TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003002560-A1 | NEW DERIVATIVES OF OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | LABORATORIOS VITA, S.A. (ES) | 2003-01-09 | — | — | WO | disclosed |
| EP-1121358-A1 | HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS | AstraZeneca AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021960-A1 | HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | CTSK 2513/4885SMN1; SMN2 2454/4885MEN1 3363/4885 |
| US-20040014746-A1 | Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections | TBCD, THPO, NISCH | CTSK 2354/4885SMN1; SMN2 4210/4885MEN1 3755/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | CTSK 345/4885SMN1; SMN2 3085/4885MEN1 4239/4885 |
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | OXA1L, Q6ZSR9, PGC | CTSK 1656/4885SMN1; SMN2 4419/4885MEN1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.